162 related articles for article (PubMed ID: 10786931)
1. Reversibility of autonomic nerve function in relation to rapid improvement of glycemic control.
Isotani H; Fukumoto Y
Horm Metab Res; 2000 Mar; 32(3):115-7. PubMed ID: 10786931
[TBL] [Abstract][Full Text] [Related]
2. Impact of disease duration on cardiovascular and pupillary autonomic nervous function in IDDM and NIDDM patients.
Straub RH; Zietz B; Palitzsch KD; Schölmerich J
Diabetes Care; 1996 Sep; 19(9):960-7. PubMed ID: 8875089
[TBL] [Abstract][Full Text] [Related]
3. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
[TBL] [Abstract][Full Text] [Related]
4. Gastric myoelectrical activity in patients with diabetes. Role of glucose control and autonomic nerve function.
Kawagishi T; Nishizawa Y; Emoto M; Maekawa K; Okuno Y; Taniwaki H; Inaba M; Ishimura E; Morii H
Diabetes Care; 1997 May; 20(5):848-54. PubMed ID: 9135954
[TBL] [Abstract][Full Text] [Related]
5. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM.
Henricsson M; Janzon L; Groop L
Diabetes Care; 1995 Dec; 18(12):1571-6. PubMed ID: 8722053
[TBL] [Abstract][Full Text] [Related]
6. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
Matsutani D; Sakamoto M; Iuchi H; Minato S; Suzuki H; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
Cardiovasc Diabetol; 2018 Mar; 17(1):36. PubMed ID: 29514695
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
8. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM).
Azad N; Emanuele NV; Abraira C; Henderson WG; Colwell J; Levin SR; Nuttall FQ; Comstock JP; Sawin CT; Silbert C; Rubino FA
J Diabetes Complications; 1999; 13(5-6):307-13. PubMed ID: 10765007
[TBL] [Abstract][Full Text] [Related]
9. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y; Matsuda M; DeFronzo RA
Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
[TBL] [Abstract][Full Text] [Related]
10. Improvement in Neuropathy Outcomes With Normalizing HbA
Ishibashi F; Taniguchi M; Kosaka A; Uetake H; Tavakoli M
Diabetes Care; 2019 Jan; 42(1):110-118. PubMed ID: 30455338
[TBL] [Abstract][Full Text] [Related]
11. [Growth hormone response to arginine administration in diabetics--with special reference to the multiple regression analysis in association with diabetic retinopathy].
Kitada M; Yasuda K; Takeda N; Miura K
Nihon Naibunpi Gakkai Zasshi; 1989 Jun; 65(6):558-71. PubMed ID: 2792459
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Segel SA; Paramore DS; Cryer PE
Diabetes; 2002 Mar; 51(3):724-33. PubMed ID: 11872673
[TBL] [Abstract][Full Text] [Related]
13. A study of autonomic neuropathy in diabetes mellitus in relation to its metabolic control.
Gupta RC; Chittora MD; Jain A
J Assoc Physicians India; 1995 Jul; 43(7):464-6. PubMed ID: 8713218
[TBL] [Abstract][Full Text] [Related]
14. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
15. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes.
Takebayashi K; Sugita R; Tayama K; Aso Y; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):351-7. PubMed ID: 14520602
[TBL] [Abstract][Full Text] [Related]
16. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus.
Ak G; Buyukberber S; Sevinc A; Turk HM; Ates M; Sari R; Savli H; Cigli A
J Diabetes Complications; 2001; 15(3):150-7. PubMed ID: 11358684
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
[TBL] [Abstract][Full Text] [Related]
18. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.
Diabetes; 1995 Aug; 44(8):968-83. PubMed ID: 7622004
[TBL] [Abstract][Full Text] [Related]
19. Unsupervised high-intensity interval training improves glycaemic control but not cardiovascular autonomic function in type 2 diabetes patients: A randomised controlled trial.
Cassidy S; Vaidya V; Houghton D; Zalewski P; Seferovic JP; Hallsworth K; MacGowan GA; Trenell MI; Jakovljevic DG
Diab Vasc Dis Res; 2019 Jan; 16(1):69-76. PubMed ID: 30541346
[TBL] [Abstract][Full Text] [Related]
20. Is the corrected QT interval a reliable indicator of the severity of diabetic autonomic neuropathy?
Bravenboer B; Hendriksen PH; Oey LP; Gispen WH; van Huffelen AC; Erkelens DW
Diabetes Care; 1993 Sep; 16(9):1249-53. PubMed ID: 8404428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
